SNOA
NASDAQ · Pharmaceuticals
Sonoma Pharmaceuticals Inc
$1.11
+0.04 (+3.74%)
Financial Highlights (FY 2026)
Revenue
56.03M
Net Income
-9,109,430
Gross Margin
38.0%
Profit Margin
-16.3%
Rev Growth
+13.8%
D/E Ratio
0.07
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 38.0% | 38.0% | 35.0% | 35.0% |
| Operating Margin | -12.6% | -11.3% | 23.2% | 24.4% |
| Profit Margin | -16.3% | -15.5% | 25.4% | 21.5% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 56.03M | 49.26M | 1.82M | 1.63M |
| Gross Profit | 21.27M | 18.70M | 638.4K | 569.1K |
| Operating Income | -7,059,865 | -5,585,827 | 423.5K | 396.5K |
| Net Income | -9,109,430 | -7,207,461 | 463.1K | 348.9K |
| Gross Margin | 38.0% | 38.0% | 35.0% | 35.0% |
| Operating Margin | -12.6% | -11.3% | 23.2% | 24.4% |
| Profit Margin | -16.3% | -15.5% | 25.4% | 21.5% |
| Rev Growth | +13.8% | +13.8% | -7.1% | +16.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 179.4K | 179.4K | 821.0K | 810.3K |
| Total Equity | 2.50M | 2.50M | 2.76M | 3.02M |
| D/E Ratio | 0.07 | 0.07 | 0.30 | 0.27 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -6,662,243 | -5,564,071 | 609.2K | 511.6K |
| Free Cash Flow | — | — | 381.4K | 338.4K |